Pacira BioSciences, Inc. (NASDAQ: PCRX)

Pacira BioSciences, Inc. is a biopharmaceutical company focused on developing and commercializing non-opioid pain management and regenerative health solutions. The company operates within the pharmaceutical and medical device industries, specializing in innovative therapies designed to address acute and chronic pain conditions. Pacira BioSciences leverages its proprietary technologies to create products that offer extended-release formulations and advanced delivery systems, aiming to improve patient outcomes while reducing reliance on opioids.

The company generates revenue through the sale of its primary products, which include EXPAREL, ZILRETTA, and iovera®. EXPAREL is a non-opioid local anesthetic indicated for postsurgical pain management, providing extended pain relief through its proprietary multivesicular liposome (pMVL) delivery technology. ZILRETTA is an extended-release formulation of triamcinolone acetonide for intra-articular injection, designed to treat osteoarthritis knee pain. iovera® is a cryotherapy-based medical device used for pain management and treatment of conditions such as osteoarthritis and spasticity. Pacira BioSciences serves a diverse customer base, including hospitals, surgical centers, and healthcare providers specializing in pain management and orthopedic care.

• Pharmaceuticals: Pacira BioSciences' pharmaceutical segment includes EXPAREL and ZILRETTA. EXPAREL is a non-opioid local anesthetic used for postsurgical pain management, leveraging the company's proprietary pMVL technology to provide extended pain relief. ZILRETTA is an extended-release formulation of triamcinolone acetonide for intra-articular injection, targeting osteoarthritis knee pain. This segment caters to the pain management market, serving hospitals, surgical centers, and healthcare providers.

• Medical Devices: The medical devices segment encompasses the iovera® system, a cryotherapy-based device designed for pain management and treatment of conditions such as osteoarthritis and spasticity. The iovera® system utilizes proprietary technology to deliver targeted cryotherapy, offering a non-opioid alternative for pain relief. This segment serves the medical device market, targeting healthcare providers and patients seeking non-pharmacological pain management solutions.

Pacira BioSciences holds a significant position within the pain management industry, competing with major pharmaceutical companies, established biotechnology firms, and specialty pharmaceutical companies. The company's competitive advantages include its proprietary pMVL technology, which enables extended-release formulations, and its focus on non-opioid pain management solutions. Additionally, Pacira BioSciences benefits from a robust intellectual property portfolio, including patents covering its proprietary technologies and manufacturing processes. The company's commitment to innovation and its ability to develop and commercialize non-opioid therapies position it as a leader in the pain management market.

The company's customer base includes hospitals, surgical centers, and healthcare providers specializing in pain management and orthopedic care. Pacira BioSciences' products are designed to meet the needs of patients and healthcare providers seeking effective and safe pain management solutions. The company's focus on non-opioid therapies aligns with the growing demand for alternative pain management options, positioning it well to capitalize on market trends and regulatory shifts towards reducing opioid use.